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3 (very distressed). We conducted a principal components
analysis (PCA) of baseline responses. Overall and sub-
scale scores were computed as average distress scores
across relevant symptoms. We assessed internal consis-
tency reliability using Cronbach’s alpha. We assessed
reproducibility by evaluating the intraclass correlation
coefﬁcient (ICC) between baseline and follow-up scores
among patients reporting no change in overall symptom
severity (n = 45). We compared mean GSAS scores across
subgroups of patients with varying levels of symptom
severity at baseline and varying degrees of heartburn relief
at follow-up using t-tests.
RESULTS: The mean (sd) age of the 278 patients was
43.6 (11.9) years, and most were female (65%) and 
Caucasian (77%). The PCA and reliability estimates 
suggested three subscales: gastrointestinal symptoms (GI),
regurgitation and heartburn (RHB), and upper respira-
tory manifestations (URM). The subscale and overall
scores were reliable (Cronbach’s alpha, ICC): GI = 0.81,
0.81; RHB = 0.79, 0.80; URM = 0.73, 0.72; Overall =
0.87, 0.85. Mean baseline overall and subscale scores
were at least 10% poorer among patients reporting
greater symptom severity (p < 0.01). Patients reporting
complete heartburn relief at follow-up reported 13% to
16% greater improvements in overall, GI, and RHB
scores than patients who did not experience complete
relief (p < 0.001).
CONCLUSIONS: This study conﬁrmed the reliability
and validity of the overall GSAS score. Further, re-
searchers may want to consider analyzing the GI, URM,
and RHB subscale scores as secondary indicators of
symptom distress.
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The risk of signiﬁcant injury to the gastrointestinal (GI)
tract from nonsteroidal anti-inﬂammatory drugs
(NSAIDs) has been well established. Patients concurrently
using warfarin or who have had a prior serious hospital
GI event are considered to be at high risk. In 2000, the
Veterans Affairs (VA) implemented treatment criteria for
the use of NSAIDs including cyclooxygenase–2 (COX-2)
inhibitors. The high-risk criteria-based therapy is sal-
salate, non-selective NSAID plus a proton pump inhibitor
(PPI), high-dose famotidine, or misoprostol or a COX-2
inhibitor.
OBJECTIVES: The purpose of this study was to assess
the level of criteria-based NSAID prescribing in high risk
patients at the New Mexico VA Healthcare System.
METHODS: Patients with concurrent prescriptions for
an NSAID and warfarin or previous hospital GI event
were identiﬁed utilizing VA databases. Current therapy
was compared to criteria-based therapy to assess level of
implementation.
RESULTS: Out of 7,625 NSAID users, 184 patients were
identiﬁed: concurrent warfarin (n = 98), prior hospital GI
event (n = 84), and concurrent warfarin with a previous
hospital GI event (n = 2). Fifty-eight percent were 
over the age of 65. The NSAIDs prescribed were ibu-
profen (42.4%), naproxen (20.1%), etodolac (16.8%),
indomethacin (8.2%), salsalate (5.4%), piroxicam
(3.3%), COX-2 inhibitors (2.1%), and sulindac (1.6%).
Criteria-based therapy was prescribed for 22% of
patients. Only 12% of warfarin patients and 33% of pre-
vious hospital GI event patients were prescribed criteria-
based therapy. Of the patients prescribed a non-selective
NSAID (n = 139), there were only 19% prescribed a 
criteria-based GI protective medication.
CONCLUSIONS: In this study, few patients, at high-risk
for GI complications due to NSAIDs, received criteria-
based therapy.
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The risk of signiﬁcant injury to the gastrointestinal (GI)
tract from nonsteroidal anti-inﬂammatory drugs
(NSAIDs) has been well established. The Veterans’ Affairs
(VA) implemented treatment criteria for the use of
NSAIDs including the new class of drugs, cyclooxyge-
nase–2 (COX-2) inhibitors. These criteria utilize a self-
administered Gastrointestinal Risk Assessment Tool (GI
Score), developed from the Arthritis, Rheumatism, and
Aging Medical Information System (ARAMIS) database,
to assess risk. This tool generates a composite score 
used to predict the 1-year risk level, level 1 (no risk) to
level 4 (substantial risk), for the potential of an NSAID-
associated GI event.
OBJECTIVES: The purpose of this study was to assess
the risk level and the level of implementation of the VA
criteria.
METHODS: The GI score was used to assess the patient’s
risk level calculated on the basis of data from VA demo-
graphic, prescription, hospitalization, clinic visits, and
active problem lists databases. Current therapy was 
compared to criteria-based therapy to assess level of
implementation.
RESULTS: There were 7,625 NSAID users in the New
Mexico VA Healthcare System: 86 previous hospitalized
GI event patients, 100 concurrent warfarin therapy
patients, 223 corticosteroid therapy patients, and 205
rheumatoid arthritis patients. Thirty-six percent of the 
VA patients were over the age of 65. The most commonly
